Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Terminated 2Completed 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 3Breast 1

Conditions

Stomach Neoplasms 2Pancreatic Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 908Carboplatin 785Paclitaxel 739pembrolizumab 738Cisplatin 707Bevacizumab 705Gemcitabine 619Docetaxel 578Rituximab 548Radiotherapy 539Dexamethasone 510Nivolumab 485Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 357Pemetrexed 334Cytarabine 334Oxaliplatin 333Lenalidomide 327Prednisone 326fludarabine phosphate 315Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Has results × titanium silicide × Clear all
NCT01285557 2024-09-19

DIGEST

Taiho Oncology, Inc.

Phase 3 Terminated
361 enrolled 18 charts
Gastrointestinal

Stomach Neoplasms

NCT03382600 2024-06-11

KEYNOTE-659

Merck Sharp & Dohme LLC

Phase 2 Completed
100 enrolled 21 charts
Gastrointestinal

Stomach Neoplasms

NCT00429858 2020-09-18

Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer

University of California, San Francisco

Phase 2 Terminated
21 enrolled 8 charts
Gastrointestinal

Pancreatic Neoplasms

NCT00438100 2015-05-29

Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer

Japan Breast Cancer Research Network

Phase 2 Completed
142 enrolled 4 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡